Weil Joachim, Schunkert Heribert
Universität Schleswig-Holstein, Campus Lübeck, Medizinische Klinik II, Lübeck.
Clin Res Cardiol. 2006;95 Suppl 4:1-15; quiz 16-7. doi: 10.1007/s00392-006-2005-z.
Heart failure is a progressive and often fatal disease process. In general, the pathophysiologic mechanisms responsible for progressive myocyte dysfunction and cell loss, cardiac remodeling and arrhythmias involve signaling mechanisms that alter myocardial gene expression. These changes in gene expression are complex and involve contractile proteins, ion channels, Ca(++) handling, apoptosis, cell metabolism, the extracellular matrix, signal transduction pathways and growth factors. In the failing heart, several changes occur in cardiac adrenergic receptor-signal transduction pathways. The most striking of these changes occur in beta-adrenergic receptors, and of the changes in beta-adrenergic receptors beta1-receptor down-regulation is the most prominent. Other changes include uncoupling of beta2-adrenergic receptors and increased activity of the inhibitory G-protein. Most of these changes appear to be related to increased activity of the adrenergic nervous system, i.e. increased exposure to norepinephrine. Antagonists of the adrenergic nervous system may improve left ventricular function and outcome in patients with heart failure. This fact supports the notion that activation of these neurohormonal systems exerts a net long-term detrimental effect on the natural history of chronic heart failure and that myocardial adrenergic desensitization phenomena are at least partially maladaptive in the setting of left ventricular dysfunction. In addition to functional alterations structural remodeling plays a major role in the progression of various heart diseases to congestive heart failure. Major contributors to this remodeling process in the heart include alterations in myocyte shape, myocyte number and extracellular matrix. However, it is unclear as to which of these changes is most critical in the development of congestive heart failure, and this may vary by etiology.
心力衰竭是一种进行性且往往致命的疾病过程。一般来说,导致心肌细胞功能逐渐失调和细胞丢失、心脏重塑及心律失常的病理生理机制涉及改变心肌基因表达的信号传导机制。这些基因表达的变化很复杂,涉及收缩蛋白、离子通道、钙离子处理、细胞凋亡、细胞代谢、细胞外基质、信号转导通路和生长因子。在衰竭心脏中,心脏肾上腺素能受体信号转导通路会发生多种变化。其中最显著的变化发生在β肾上腺素能受体,而β肾上腺素能受体变化中β1受体下调最为突出。其他变化包括β2肾上腺素能受体解偶联以及抑制性G蛋白活性增加。这些变化大多似乎与肾上腺素能神经系统活性增加有关,即去甲肾上腺素暴露增加。肾上腺素能神经系统拮抗剂可能改善心力衰竭患者的左心室功能和预后。这一事实支持了这样一种观点,即这些神经激素系统的激活对慢性心力衰竭的自然病程产生净长期有害影响,并且在左心室功能障碍情况下心肌肾上腺素能脱敏现象至少部分是适应不良的。除功能改变外,结构重塑在各种心脏病进展为充血性心力衰竭过程中起主要作用。心脏这种重塑过程的主要促成因素包括心肌细胞形状、心肌细胞数量和细胞外基质的改变。然而,尚不清楚这些变化中哪一个在充血性心力衰竭发展中最为关键,这可能因病因不同而有所差异。